Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism

Renal Failure

Volumn 36, Issue 1, 2014, Pages 131-138

  Yousaf, Farhanah ^a   Charytan, Chaim ^a  

^a NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

Bone disease; Calcium; Cardiovascular disease; End stage renal disease; Parathyroid hormone; Vascular calcification

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO; VITAMIN D;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONSTIPATION; CORONARY ARTERY CALCIFICATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS PATIENT; HIP FRACTURE; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LOW DRUG DOSE; META ANALYSIS (TOPIC); NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM; SPINE FRACTURE; STEADY STATE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

BONE DENSITY; CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; NAPHTHALENES; PRACTICE GUIDELINES AS TOPIC;

EID: 84889575769     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.832319     Document Type: Review

References (116)

1. Coen G, Ballanti P, Bonucci E, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002; 91(1):103-111.
2. Craver L, Marco MP, Mart?́nez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22(4):1171-1176.
3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38. Epub 2006 Nov 8. Erratum in: Kidney Int. 2009;75(11):1237.
4. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44(2):250-256.
5. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7): 2205-2215.
6. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant. 2012; 27(5):1715-1720.
7. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990;38(2):193-211.
8. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int. 1993; 43(2):436-442.
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607-617.
10. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca-PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131-2138.
11. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731-1740.
12. Block GA, Klassen PS, Lazarus JM, OfsthunN, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
13. Jean G, Bresson E, Lorriaux C, et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract. 2012; 120(3):c132-c138.
14. Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs. 2005;65(2):271-281. Review.
15. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005; 16(3):800-807.
16. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46(1):58-67.
17. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197-207.
18. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20(10):2186-2193.
19. Sterrett JR, Strom J, Stummvoll HK, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2007;68(1):10-17.
20. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009;24(3):982-989.
21. Li D, Shao L, Zhou H, Jiang W, Zhang W, Xu Y. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine. 2013;43(1):68-77.
22. Lazar ES, Stankus N. Cinacalcet-induced hungry bone syndrome. Semin Dial. 2007;20(1):83-85.
23. Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet-proposal for an improved monitoring. Clin Lab. 2006;52(11-12):583- 587.
24. Zhang Q, Li M, You L, et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One. 2012;7(10):e48070.
25. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67(3):1179-1187.
26. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-530.
27. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.
28. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009; 24(5):1506-1523.
29. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;Aug:(113):S1-S130.
30. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25(4):595-602.
31. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant. 2004;19(Suppl 5): V15-V19.
32. Arenas MD, Alvarez-Ude F, Gil MT, et al. Application of NKF-K/DOQI clinical practice guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three hemodialysis units. Nephrol Dial Transplant. 2006;21(6):1663-1668.
33. Arenas MD, Alvarez-Ude F, Gil MT, et al. Implementation of 'K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease' after the introduction of cinacalcet in a population of patients on chronic hemodialysis. Nephrol Dial Transplant. 2007;22(6):1639-1644.
34. Arenas MD, Alvarez-Ude F, Torregrosa V, et al. Consequences of the implementation of K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease in a population of patients on chronic hemodialysis. J Nephrol. 2007;20(4):453-461.
35. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium-phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63(1): 248-254.
36. Sprague SM, Evenepoel P, Curzi MP, et al. Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009;4(9):1465-1476.
37. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67(2):760-771.
38. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008; 3(1):36-45.
39. Zitt E, Jäger C, Rosenkranz AR, et al. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients-results of the Austrian cohort of the ECHO study. Wien Klin Wochenschr. 2011;123(1-2):45-52.
40. Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012; 27(8):3270-3278.
41. Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008; 3(6):1718-1725.
42. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423-1429.
43. Barsotti G, Cupisti A, Morelli E, et al. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation. Nephron. 1998;79(2):137-141.
44. Combe C, Morel D, de Précigout V, et al. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol). Nephron. 1995;70(3):287-295.
45. Sherman RA, Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis. 2009;54(1):18-23.
46. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4(8):1370-1373.
47. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511-1518.
48. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519-530. Review.
49. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009; 54(4):619-637. Review.
50. Koiwa F, Kazama JJ, Tokumoto A, et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial. 2005;9(4):336-339.
51. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286-291.
52. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23(8):1407-1415.
53. Zitt E, Fouque D, Jacobson SH, et al. Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J. 2013;6(3):287-294.
54. Cooper K, Quarles D, Kubo Y, Tomlin H, Goodman W. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients. Nephron Clin Pract. 2012;121(3-4):c124-c130.
55. Spiegel DM, McPhatter L, Allison A, Drumheller JC, Lockridge R. A computerized treatment algorithm trial to optimize mineral metabolism in ESRD. Clin J Am Soc Nephrol. 2012; 7(4):632-639.
56. HryszkoT, Brzosko S, Rydzewska-Rosolowska A, Koc-Zorawska E, Mysliwiec M. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol. 2012;44(5):1479-1486.
57. Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract Nephrol. 2008;4(7):364-365. Review.
58. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197-207.
59. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol. 2010;5(1):110-116.
60. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9 (12 Suppl):S16-S23.
61. Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004;19 (Suppl 5):V59-S66.
62. Coen G, Manni M, Mantella D, et al. Are PTH serum levels predictive of coronary calcifications in hemodialysis patients? Nephrol Dial Transplant. 2007;22(11):3262-3267.
63. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-E17.
64. Neves KR, Graciolli FG, dos Reis LM, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007;71(12):1262-1270.
65. Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011;109(1):e1-e12.
66. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11): 2857-2867.
67. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213-216.
68. Ribeiro S, Ramos A, Brandão A, et al. Cardiac valve calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant. 1998;13(8):2037-2040.
69. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20): 1478-1483.
70. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6): 1241-1248.
71. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27(3):394-401
72. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003;14(1):159-168.
73. Tsuruta Y, Ohbayashi T, Fujii M, et al. Change in coronary artery calcification score due to cinacalcet hydrochloride administration. Ther Apher Dial. 2008;12(Suppl 1):S34-S37.
74. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4): 1327-1339.
75. Bonet J, Bayés B, Fernández-Crespo P, Casals M, López-Ayerbe J, Romero R. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism-results of a small-scale, prospective, observational study. Clin Nephrol. 2011;75(3):181-187.
76. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793-1800.
77. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010;78(6):578-589.
78. The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-2494.
79. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
80. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in hemodialysis patients. Nephrol Dial Transplant. 2010; 25(8):2679-2685.
81. Jean G, Bresson E, Lorriaux C, et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract. 2012; 120(3):c132-c138.
82. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long hemodialysis patients. Nephrol Dial Transplant. 2009; 24(9):2792-2796.
83. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-hemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24(3): 948-955.
84. Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial Int. 2012;16(1):53-58.
85. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11): 4393-4408.
86. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545-2552.
87. Yuan Q, Sato T, Densmore M, et al. FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J Bone Miner Res. 2011;26(9):2026-2035.
88. Prié D, Ureña Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009;75(9):882-889.
89. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-435.
90. Sitara D, Razzaque MS, St-Arnaud R, et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol. 2006;169(6): 2161-2170.
91. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4): F882-F889.
92. Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004;44(3):481-487.
93. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737-747.
94. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22(1):124-136.
95. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol. 2010;5(1):110-116.
96. Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005;101(2):c94-c99.
97. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in hemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27(2):784-790.
98. Foldes AJ, Arnon E, Popovtzer MM. Reduced speed of sound in tibial bone of hemodialysed patients: association with serum PTH level. Nephrol Dial Transplant. 1996;11(7):1318-1321.
99. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006; 70(7):1358-1366.
100. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006; 47(1):149-156.
101. Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A; K Study Group. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial. 2008;12(Suppl 1):S38-S43.
102. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2005;20(6):1232-1237.
103. Ishimura E, Okuno S, Tsuboniwa N, et al. Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2011;76(4): 259-265.
104. Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S157-S163.
105. Kakuta T, Tanaka R, Kanai G, et al. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism? Ther Apher Dial. 2009;13(Suppl 1):S20-S27.
106. Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008; 23(1):328-335.
107. Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436.
108. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5): 397-411.
109. Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis. 2007;49(6):801-813.
110. Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ. 2012;15(3):509-520.
111. Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health. 2008;11(5):800-808.
112. Iannazzo S, Carsi M, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Appl Health Econ Health Policy. 2012; 10(2):127-138.
113. Garside R, Pitt M, Anderson R, et al. The effectiveness and costeffectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic reviewand economic evaluation. Health Technol Assess. 2007;11(18):iii, xi-xiii, 1-167.
114. Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis. 2010;56(6):1108-1116.
115. Roggeri DP, Mazzaferro S, Brancaccio D, et al. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. J Med Econ. 2012;15(6):1110-1117.
116. Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5(12): 2305-2314.